Suzhou Alphamab Co., Ltd.
PrivateLast Round
IPO
Dec 11, 2019
Est. Valuation
$1.16B
Total Funding Raised
$160M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Suzhou Alphamab Co., Ltd. operates in Healthcare & Life Sciences and is based in Suzhou. Its latest recorded funding round was a Series B round in May 2019.
Suzhou Alphamab Co., Ltd. is a biopharmaceutical company that provides research and industrialization services for antibody and protein macromolecule drugs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Suzhou Alphamab Co., Ltd. Comparables
Compare Suzhou Alphamab Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alphamab Oncology | 93% | |
| Akeso, Inc. | 86% | |
| 3D Medicines Inc. | 84% |
For institutional investors. Book with your work email.
Suzhou Alphamab Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Dec 11, 2019 | ||||
| Series B | May 28, 2019 | ||||
| Series A | Nov 16, 2018 |
For institutional investors. Book with your work email.
Suzhou Alphamab Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lake Bleu Capital | IPO |
| PAG | Series B, Series A |
| OrbiMed | Series A, IPO |
| Advantech Capital | Series B, Series A |
| Janchor Partners | Series A |
| Greenwoods Asset Management | IPO |
| Hudson Bay Capital Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 21, 2026
Open roles increased to 10, representing 67% of headcount.
- Dec 4, 2025
Monthly visitors grew 350% MoM, reaching 1.5K.
For institutional investors. Book with your work email.
Suzhou Alphamab Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Suzhou Alphamab Co., Ltd.'s valuation, stock price, and market status.
Is Suzhou Alphamab Co., Ltd. a public or private company?
Suzhou Alphamab Co., Ltd. is a private company.
What is the current stock price of Suzhou Alphamab Co., Ltd.?
Suzhou Alphamab Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Suzhou Alphamab Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Suzhou Alphamab Co., Ltd. worth (valuation)?
Suzhou Alphamab Co., Ltd.'s valuation is estimated at $1.2B based on funding round data.
Can I buy Suzhou Alphamab Co., Ltd. stock?
Suzhou Alphamab Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Suzhou Alphamab Co., Ltd.'s last funding round?
Suzhou Alphamab Co., Ltd.'s most recent funding round was IPO on December 11, 2019.
Who are the main investors in Suzhou Alphamab Co., Ltd.?
Key investors in Suzhou Alphamab Co., Ltd. include Hudson Bay Capital Management.
Will Suzhou Alphamab Co., Ltd. IPO soon?
No public IPO plans have been announced for Suzhou Alphamab Co., Ltd..
How can I track Suzhou Alphamab Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Suzhou Alphamab Co., Ltd.'s shares on secondary markets.